Anthony Strzalek
Why ClotTriever is a “gamechanger” for the treatment of deep vein thrombosis
Andrew Wigham (Oxfor...
ESC 2021: Systematic pressure wire assessment has no additional benefit at diagnostic angiography
Adding systematic fra...
ESC 2021: Edoxaban shown to be noninferior to warfarin for adverse events after TAVI
Edoxaban is noninferi...
Randomised trials “instrumental” in future research of tricuspid valve repair
Speaking to Cardiova...
Selecting the right valve for the patient is key for a successful TAVI program
NOTE: This video is ONLY ...
First-in-human results show no transcaval-related bleeding after TAVR with novel closure device
Toby Rogers (Washingt...

















